secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2025-08-26T23:59:59+00:00
Accession:  0000950170-25-111319
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell Therapeutics enters collaboration with WDI for hearing loss program; up to $12M funding
--------------------------------------------------------------------------------

- Multi-year research collaboration with William Demant Invest 2 Aps to advance ReSonance (ANPI) preclinical program for hearing loss.
- WDI will fund up to $12 million in research costs over the approximate three-year term.
- Objective: complete preclinical phase to achieve readiness for potential human clinical trials.
- IP: jointly owned project results; each party retains background IP and platform technology.
- If a party abandons, the continuing party may purchase the abandoning party's IP interest in the project.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000095017025111319/0000950170-25-111319-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000095017025111319/lctx-20250826.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-111319

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer